MIMETAS B.V., Leiden, the Netherlands.
Department of Pharmacology and Toxicology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
J Pharm Sci. 2021 Apr;110(4):1601-1614. doi: 10.1016/j.xphs.2021.01.028. Epub 2021 Feb 3.
Proximal tubule epithelial cells (PTEC) are susceptible to drug-induced kidney injury (DIKI). Cell-based, two-dimensional (2D) in vitro PTEC models are often poor predictors of DIKI, probably due to the lack of physiological architecture and flow. Here, we assessed a high throughput, 3D microfluidic platform (Nephroscreen) for the detection of DIKI in pharmaceutical development. This system was established with four model nephrotoxic drugs (cisplatin, tenofovir, tobramycin and cyclosporin A) and tested with eight pharmaceutical compounds. Measured parameters included cell viability, release of lactate dehydrogenase (LDH) and N-acetyl-β-d-glucosaminidase (NAG), barrier integrity, release of specific miRNAs, and gene expression of toxicity markers. Drug-transporter interactions for P-gp and MRP2/4 were also determined. The most predictive read outs for DIKI were a combination of cell viability, LDH and miRNA release. In conclusion, Nephroscreen detected DIKI in a robust manner, is compatible with automated pipetting, proved to be amenable to long-term experiments, and was easily transferred between laboratories. This proof-of-concept-study demonstrated the usability and reproducibility of Nephroscreen for the detection of DIKI and drug-transporter interactions. Nephroscreen it represents a valuable tool towards replacing animal testing and supporting the 3Rs (Reduce, Refine and Replace animal experimentation).
近端肾小管上皮细胞 (PTEC) 易受药物引起的肾损伤 (DIKI) 的影响。基于细胞的二维 (2D) 体外 PTEC 模型通常不能很好地预测 DIKI,这可能是由于缺乏生理结构和流动。在这里,我们评估了高通量、3D 微流控平台 (Nephroscreen) 在药物开发中检测 DIKI 的能力。该系统使用四种模型肾毒性药物(顺铂、替诺福韦、妥布霉素和环孢素 A)建立,并测试了八种药物化合物。测量的参数包括细胞活力、乳酸脱氢酶 (LDH) 和 N-乙酰-β-d-氨基葡萄糖苷酶 (NAG) 的释放、屏障完整性、特定 miRNA 的释放以及毒性标志物的基因表达。还确定了 P-糖蛋白和 MRP2/4 的药物转运蛋白相互作用。对 DIKI 最具预测性的读数是细胞活力、LDH 和 miRNA 释放的组合。总之,Nephroscreen 以稳健的方式检测到 DIKI,与自动化移液兼容,证明适用于长期实验,并且可以在实验室之间轻松转移。这项概念验证研究证明了 Nephroscreen 用于检测 DIKI 和药物转运蛋白相互作用的可用性和可重复性。Nephroscreen 代表了一种有价值的工具,可以替代动物试验,并支持 3R(减少、优化和替代动物实验)。